Glaukos Corporation (GKOS) shares fell over 5% on Thursday, January 15, 2026, to $104.43, as investors reacted to the company's preliminary fourth-quarter 2025 financial results.
Despite reporting revenue that significantly exceeded Wall Street estimates and reaffirming its 2026 outlook, the stock experienced a “sell-the-news” pullback following an initial 9% slide in after-hours trading earlier this week.
| GKOS Key Metrics | |
| Current Price | $104.43 |
| Daily Change | -5.26% 🔴 |
| Day Range | $93.96 – $105.00 |
| 52-Week Range | $73.16 – $163.71 |
The drop comes after a period of strong performance, with the stock up nearly 20% over the last three months.
According to the company’s official announcement, preliminary fourth-quarter net sales reached approximately $143 million, representing 36% year-over-year growth and comfortably beating analyst estimates of $129.4 million.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | -5.99% | 🔴 |
| 3 Months | +19.97% | 🟢 |
| 6 Months | +3.92% | 🟢 |
| 1 Year | -32.60% | 🔴 |
The immediate market volatility appears to be a correction after months of buildup. The company's reaffirmed 2026 revenue guidance simply matched existing analyst expectations rather than offering a fresh upward surprise.
Key Takeaways
- Glaukos (GKOS) stock dropped over 5% today to $104.43 following a strong earnings beat.
- Preliminary Q4 2025 sales hit $143 million, a 36% increase year-over-year.
- The iDose TR product contributed $45 million to the quarter's total revenue.
- The company reaffirmed its 2026 revenue guidance of $600 million to $620 million.
- Major analyst firms, including Needham and Truist Securities, raised their price targets after the results.
What Triggered Glaukos (GKOS) Stock's Recent Drop?
The primary catalyst for the decline was the release of preliminary, unaudited fourth-quarter and full-year 2025 results on January 13, 2026.
While the top-line numbers were strong, the stock fell nearly 9% in after-hours trading immediately following the report.
This reaction is often characterized by market analysts as a “sell-the-news” event. Investors calculate stock profit and lock in gains after a period of significant price appreciation leading up to a known announcement.
Market sentiment was also influenced by the 2026 revenue guidance. Glaukos reaffirmed its outlook of $600 million to $620 million, which aligns closely with the consensus analyst expectation of $612.3 million.
In high-growth medtech stocks, a failure to raise guidance alongside an earnings beat can sometimes lead to a technical pullback as short-term traders exit positions.
Glaukos' Robust Preliminary Q4 & FY25 Results: A Closer Look
Despite the stock price movement, Glaukos reported record-breaking operational figures. Full-year 2025 preliminary sales reached $507 million, a 32% increase from 2024.
This growth was driven largely by the U.S. Glaucoma segment, which brought in $86 million in the fourth quarter alone. International Glaucoma sales contributed another $33 million, while the Corneal Health division added $24 million.
The company’s flagship product, iDose TR, continues to be a central growth driver. The intracameral pharmaceutical for glaucoma contributed $45 million in the fourth quarter and approximately $136 million for the full year 2025.
Glaukos Chairman and CEO Thomas Burns noted that these results leave the company “well positioned to sustain our strong growth momentum in 2026 and beyond.”
What Are Analysts Saying About GKOS After the Earnings Beat?
Wall Street analysts remain largely bullish on the company’s long-term prospects. Following the report, Needham raised its price target for Glaukos to $125 from $117, citing positive feedback on the Epioxa pipeline and the current Photrexa product line.
According to financial coverage from Investing.com, analyst David Rescott of Truist Securities also raised his price target to $105 from $100, reiterating a Buy rating.
Other major firms have also maintained high expectations. Piper Sandler reiterated an Overweight rating with a $165 price target, naming Glaukos a “2026 Top Idea” within the Medtech sector.
BTIG and Stifel maintained their Buy ratings with price targets of $116 and $115, respectively. Stifel noted that reimbursement remains a temporary hurdle for iDose TR.
The consensus remains focused on the company’s innovation pipeline. Many investors monitor this using the best stock analysis apps to track ongoing rating changes.
How Does Glaukos (GKOS) Compare to its Medical Device Peers?
The stock's over 5% decline today stands in contrast to the broader Medical Devices industry, which saw an average change of just -0.44%.
While some peers like SI-BONE (SIBN) and Alphatec (ATEC) fell around 3%, others posted gains. Medtronic (MDT) rose over 2%, and Globus Medical (GMED) climbed roughly 2.5%.
| Company | Symbol | Daily Change | Performance |
|---|---|---|---|
| Medtronic | MDT | +2.41% | 🟢 |
| Globus Medical | GMED | +2.55% | 🟢 |
| SI-BONE | SIBN | -3.08% | 🔴 |
| Alphatec | ATEC | -2.98% | 🔴 |
| Industry Avg | – | -0.44% | – |
| Glaukos | GKOS | -5.26% | 🔴 |
Compared to other high-growth peers, Glaukos has faced a more volatile 12-month period, with its price down about 33% over the last year.
However, its recent three-month rally suggests that it is recovering more aggressively than some competitors like TransMedics Group (TMDX). Investors should still consider what beta in stocks implies regarding this relative volatility.
Is GKOS a Buy After This Pullback? The Bull vs. Bear Case
The bull case for Glaukos centers on its rapid revenue expansion and strong liquidity. The company ended the year with approximately $283 million in cash and no debt.
With a revenue growth rate of over 30% over the last twelve months and the upcoming launch of Epioxa in Q1 2026, bulls argue that the current pullback is a healthy consolidation.
Conversely, the bear case highlights that Glaukos remains unprofitable despite its top-line success. Some investors are cautious about the company’s valuation given the “sell-the-news” reaction.
The stock's failure to maintain its post-earnings momentum suggests that the market may be waiting for more concrete signs of a path to profitability.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Strong 36% Q4 revenue growth beating estimates | • Company remains net unprofitable |
| • Robust liquidity: $283M cash and no debt | • “Sell-the-news” volatility after 3-month rally |
| • iDose TR contribution ($136M for FY2025) | • Reimbursement hurdles for iDose TR outcomes |
| • Positive pipeline momentum (Epioxa launch Q1) | • 1-year price performance down over 32% |
What Should Glaukos Investors Watch Next?
Looking forward, the launch of Epioxa in the first quarter of 2026 will be a critical milestone for the Corneal Health segment.
Investors will also be monitoring the company's ability to hit its reaffirmed 2026 revenue target of $600 million to $620 million.
Any shifts in the reimbursement landscape for iDose TR or further clinical data from the MIGS platform could also serve as significant catalysts.
The Bottom Line
Glaukos Corporation’s recent stock decline appears to be a technical reaction to a strong performance report rather than a sign of fundamental weakness.
While the “sell-the-news” dynamic has pressured shares in the short term, the company’s 36% quarterly revenue growth and strong cash position provide a robust foundation.
Investors should weigh the company's impressive top-line momentum against its current lack of profitability as it enters a pivotal 2026 fiscal year.
